QLS2309
/ Qilu Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
January 03, 2026
A Phase I Study of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies
(clinicaltrials.gov)
- P1 | N=186 | Recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Hematological Malignancies • Oncology
September 16, 2025
A Phase I Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies
(clinicaltrials.gov)
- P1 | N=186 | Not yet recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.
New P1 trial • Hematological Malignancies • Oncology
1 to 2
Of
2
Go to page
1